This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nagy, G Articles by Gergely, P Search for Related Content PubMed PubMed Citation Articles by Nagy, G Articles by Gergely, P Social Bookmarking                         What's this?

Usefulness of detection of complement activation products in evaluating SLE activity

Central Laboratory of Immunology, Semmelweis University of Medicine, Maria u 41, H-1085 Budapest, Hungary

M Brózik

Central Laboratory of Immunology, Semmelweis University of Medicine, Budapest, Hugary

L Varga

National Institute of Haematology and Immunology, Budapest, Hungary

G Füst

3rd Department of Internal Medicine, Semmelweis University of Medicine, Budapest, Hungary

M Kirschfink

Ruprecht-Karls Universität, Heidelberg, Germany;

E Kiss

3rd Department of Internal Medicine, University Medical School of Debrecen, Debrecen, Hungary

P Gergely

Central Laboratory of Immunology, Semmelweis University of Medicine, Budapest, Hugary

Complement activation products, such as C1rs-C1inh, specific for the activation of the classical pathway, C3b(Bb)P, specific for the activation of the alternative pathway and SC5b-9, specific for common terminal pathway of the complement cascade, were measured in healthy donors and in patients with clinically active and inactive systemic lupus erythematosus (SLE). Plasma levels of C3b(Bb)P and SC5b-9 were moderately, those of C1rs-C1inhibitor (C1rs-C1inh) were markedly elevated in patients with clinically inactive SLE, compared with healthy controls. The difference between active and inactive stages of the disease was best reflected by C3b(Bb)P plasma concentration (P < 0.001), which also showed the highest correlation with the SLEDAI (Rs = 0.41 P < 0.001) and which was the most useful in distinguishing active and inactive sample pairs as well. The difference between SC5b-9 levels in the active and inactive stages was also significant (P = 0.007), while that of C1rs-C1inh did not differ significantly (P = 0.136). The correlation of the SLEDAI with SC5b-9 was 0.3 (P = 0.015), while with C1rs-C1inh it was 0.21 (P = 0.089). These findings suggest that the measurement of complement activation products, especially that of the alternative pathway, are sensitive markers of the activity of SLE and can be used for clinical purposes.

Key Words: C3b(Bb)P • C1rs-C1inh • SC5b-9 • SLE activity

Lupus, Vol. 9, No. 1, 19-25 (2000)
DOI: 10.1177/096120330000900105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S Manzi, J M Ahearn, and J Salmon New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 298 - 303. [Abstract] [PDF]